Lyra Therapeutics (LYRA) Equity Ratio (2021 - 2025)
Historic Equity Ratio for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 0.1.
- Lyra Therapeutics' Equity Ratio fell 13782.09% to 0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1, marking a year-over-year decrease of 13782.09%. This contributed to the annual value of 0.17 for FY2024, which is 7213.22% down from last year.
- Per Lyra Therapeutics' latest filing, its Equity Ratio stood at 0.1 for Q3 2025, which was down 13782.09% from 0.03 recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Equity Ratio ranged from a high of 0.93 in Q1 2021 and a low of 0.1 during Q3 2025
- Over the past 5 years, Lyra Therapeutics' median Equity Ratio value was 0.63 (recorded in 2023), while the average stood at 0.52.
- Per our database at Business Quant, Lyra Therapeutics' Equity Ratio soared by 4333.27% in 2023 and then plummeted by 13782.09% in 2025.
- Quarter analysis of 5 years shows Lyra Therapeutics' Equity Ratio stood at 0.63 in 2021, then rose by 17.41% to 0.73 in 2022, then fell by 14.61% to 0.63 in 2023, then crashed by 72.13% to 0.17 in 2024, then crashed by 156.66% to 0.1 in 2025.
- Its Equity Ratio was 0.1 in Q3 2025, compared to 0.03 in Q2 2025 and 0.07 in Q1 2025.